Skip to main content
OpenTrials
Completed

NCT Number: NCT05013281

Suprachoroidal Hemorrhage Associated With Pars Plana Vitrectomy

To analyze the characteristics, related risk factors, and prognosis of suprachoroidal hemorrhage (SCH) associated with pars plana vitrectomy (PPV).

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Beijing Tongren Hospital

Beijing, Beijing Municipality, 100730, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Suprachoroidal hemorrhage associated with pars plana vitrectomy

Exclusion criteria

  • Patients with eye trauma-related Suprachoroidal hemorrhage were excluded.

Treatment and study plan

Suprachoroidal hemorrhage associated with pars plana vitrectomy

Procedure

SCH has a higher incidence rate after a second intraocular surgery in a vitrectomized eye which is associated with the lack of vitreous support and easier fluctuation of intraocular pressure. SCH associated with PPV is more localized and has a relatively good prognosis; high myopia and aphakic/ pseudophakic eyes are risk factors. Active treatment can effectively improve visual prognosis.

Primary outcomes

  1. pathogenesis

    Time frame: baseline

    pathogenesis of PPV-related SCH and incidence of PPV-related SCH

Secondary outcomes

  1. vision acuity

    Time frame: up to 7 weeks

    the final vision acuity

Sponsors and collaborators

Lead sponsor

Beijing Tongren Hospital

Other

Registry information

Important dates

Study start
2010
Primary completion
2020
Study completion
2021
First posted
Aug 19, 2021
Registry last updated
Aug 19, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.